The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. RESULTS: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P<0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P<0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10%) in the elotuzumab group and were grade 1 or 2 in 29 patients. CONCLUSIONS: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number, NCT01239797.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike daratumumab, elotuzumab does not have single-agent activity but shows synergistic activity when combined with Rd (Table 8).84”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [84]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Elotuzumab targets SLAMF7; daratumumab and isatuximab target CD38 respectively.84–87”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [30]
In the citing paper
“Elotuzumab has been proposed to function at least partially through upregulation of IL-2 production by T cells and stimulation of natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC)68–70.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationCS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S. M., Draksharapu, A., Shum, B. P., Huseni, M. A., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 558
SLAM Family Receptors and SAP Adaptors in Immunity
Cannons, J. L., Tangye, S. G., & Schwartzberg, P. L. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101302 · Cited by 502
Tai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472
Self-citationVoskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 465
Dimopoulos, M. A., Chen, C. L., Spencer, A. G., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 366
Self-citationCollins, S. M., Bakan, C. E., Swartzel, G. D., Hofmeister, C. C., Efebera, Y. A., Kwon, H., Starling, G. C., Ciarlariello, D., Bhaskar, S., Briercheck, E. L., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1493-8 · Cited by 296
Richardson, P. G. G., Baz, R., Wang, M. L., Jakubowiak, A. J., Laubach, J. P., Harvey, R. D., Talpaz, M., Berg, D. T., Liu, G., Jiang, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548826 · Cited by 202
Self-citationPérez‐Quintero, L., Roncagalli, R., Guo, H., Latour, S., Davidson, D., & Veillette, A. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132038 · Cited by 96
Cited by
Sorted by citations
Items 201–300 of 1,000
New Insights in Anti-Angiogenesis in Multiple Myeloma
Ribatti, D., & Vacca, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072031 · Cited by 62
Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
Zhang, K. W., Stockerl-Goldstein, K. E., & Lenihan, D. J. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.002 · Cited by 62
Botta, C., Ciliberto, D., Rossi, M., Staropoli, N., Cucè, M., Galeano, T., Tagliaferri, P., & Tassone, P. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003905 · Cited by 60
Chimeric Antigen Receptor ( CAR ) therapy for multiple myeloma
Atanackovic, D., Radhakrishnan, S. V., Bhardwaj, N., & Luetkens, T. (2016) · British Journal of Haematology · doi:10.1111/bjh.13889 · Cited by 60
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma
Wanchoo, R., Abudayyeh, A., Doshi, M. D., Edeani, A., Glezerman, I. G., Monga, D., Rosner, M. H., & Jhaveri, K. D. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06100616 · Cited by 61
Xing, L., Lin, L., Yu, T., Li, Y., Cho, S., Liu, J., Wen, K., Hsieh, P. A., Kinneer, K., Munshi, N. C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0745-9 · Cited by 61
Self-citationSLAM-family receptors come of age as a potential molecular target in cancer immunotherapy
Farhangnia, P., Ghomi, S. M., Mollazadehghomi, S., Nickho, H., Akbarpour, M., & Delbandi, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1174138 · Cited by 59
Allogeneic stem cell transplantation for multiple myeloma: is there a future?
Dhakal, B., Vesole, D. H., & Hari, P. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.325 · Cited by 61
Chng, W.-J., Goldschmidt, H., Dimopoulos, M. A., Moreau, P., Joshua, D. E., Palumbo, A. P., Facon, T. T. F., Ludwig, H., Pour, L., Niesvizky, R., et al. (2016) · Leukemia · doi:10.1038/leu.2016.390 · Cited by 59
Self-citationImmunopathogenesis and immunotherapy of multiple myeloma
Tamura, H. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2405-7 · Cited by 59
Update on the role of lenalidomide in patients with multiple myeloma
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718775629 · Cited by 59
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
Abramson, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123924 · Cited by 59
Kumar, S. K., Moreau, P., Hari, P., Mateos, M., Ludwig, H., Shustik, C., Masszi, T., Spencer, A. G., Hájek, R., Romeril, K. R., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14733 · Cited by 59
Self-citationPerspectives on the Treatment of Multiple Myeloma
Rafae, A., van Rhee, F., & Hadidi, S. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad306 · Cited by 65
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth
Turner, T. B., Meza‐Perez, S., Londoño, A. I., Katre, A. K., Lever, J. E. P., Smith, H. J., Forero, A., Norian, L. A., Straughn, J. M., Buchsbaum, D. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17395 · Cited by 58
McCudden, C. R., Jacobs, J. F. M., Keren, D. F., Caillon, H., Dejoie, T., & Andersen, K. (2017) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2017.08.013 · Cited by 57
Current developments in immunotherapy in the treatment of multiple myeloma
Köhler, M., Greil, C., Hudecek, M., Lonial, S., Raje, N. S., Wäsch, R., & Engelhardt, M. M. (2018) · Cancer · doi:10.1002/cncr.31243 · Cited by 58
Self-citationDeveloping next generation immunomodulatory drugs and their combinations in multiple myeloma
Thakurta, A., Pierceall, W. E., Amatangelo, M. D., Flynt, E., & Agarwal, A. (2021) · Oncotarget · doi:10.18632/oncotarget.27973 · Cited by 59
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action
Wudhikarn, K., Wills, B., & Lesokhin, A. M. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101143 · Cited by 56
Treatment of relapsed multiple myeloma: Evidence-based recommendations
Durer, C., Durer, S., Lee, S., Chakraborty, R., Malik, M. N., Rafae, A., Zar, M. A., Kamal, A., Rosko, N., Samaras, C. J., et al. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100616 · Cited by 56
Nijhof, I. S., Franssen, L. E., Levin, M., Bos, G. M. J., Broijl, A., Klein, S. K., Koene, H. R., Bloem, A. C., Beeker, A., Faber, L. M., et al. (2016) · Blood · doi:10.1182/blood-2016-07-729236 · Cited by 55
Molecular Players in Hematologic Tumor Cell Trafficking
Redondo-Muñóz, J., Garcı́a-Pardo, A., & Teixidó, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00156 · Cited by 57
NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
Zambello, R., Barilà, G., Manni, S., Piazza, F., & Semenzato, G. (2020) · Cells · doi:10.3390/cells9030768 · Cited by 44
Balmaceda, N. B., Aziz, M., Chandrasekar, V. T., McClune, B. L., Kambhampati, S., Shune, L. O., Abdallah, A.-O. A., Anwer, F., Majeed, A., Qazilbash, M. H., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08451-x · Cited by 57
Clinical impact of serum soluble SLAMF7 in multiple myeloma
Ishibashi, M., Soeda, S., Sasaki, M., Handa, H., Imai, Y., Tanaka, N., Tanosaki, S., Ito, S., Odajima, T., Sugimori, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26196 · Cited by 54
Selective elimination of immunosuppressive T cells in patients with multiple myeloma
Awwad, M. H. S., Mahmoud, A., Bruns, H., Echchannaoui, H., Kriegsmann, K., Lutz, R., Raab, M. S., Bertsch, U., Munder, M., Jauch, A. S., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01172-x · Cited by 54
Current treatments for renal failure due to multiple myeloma
Gavriatopoulou, M., Terpos, E., Kastritis, E., & Dimopoulos, M. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1236915 · Cited by 54
Self-citationHow I manage the toxicities of myeloma drugs
Delforge, M., & Ludwig, H. (2017) · Blood · doi:10.1182/blood-2017-01-725705 · Cited by 55
PD-1 blockade enhances elotuzumab efficacy in mouse tumor models
Bezman, N., Jhatakia, A., Kearney, A. Y., Brender, T., Maurer, M. F., Henning, K. A., Jenkins, M. R., Rogers, A. J., Neeson, P. J., Korman, A. J., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017004382 · Cited by 54
BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
Cho, S., Lin, L., Xing, L., Li, Y., Yu, T., Anderson, K. C., & Tai, Y. (2020) · Cancers · doi:10.3390/cancers12061473 · Cited by 57
Self-citationCAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update
Cohen, A. D. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200889 · Cited by 54
Nobari, S. T., Nojadeh, J. N., & Talebi, M. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03285-y · Cited by 53
Multiple myeloma in the very elderly patient: challenges and solutions
King, A. J., Eyre, T. A., Sharpley, F. A., Watson, C. S., Ramasamy, K., & Willan, J. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s89465 · Cited by 53
Zhong, Y., Meng, F., Zhang, W., Li, B., van Hest, J. C. M., & Zhong, Z. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.004 · Cited by 53
Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
Little, J. S., Weiss, Z., & Hammond, S. P. (2021) · Journal of Fungi · doi:10.3390/jof7121058 · Cited by 55
The emerging therapeutic landscape of relapsed/refractory multiple myeloma
Tanenbaum, B., Miett, T., & Patel, S. A. (2022) · Annals of Hematology · doi:10.1007/s00277-022-05058-5 · Cited by 57
Naci, H., Zhang, Y., Woloshin, S., Guan, X., Xu, Z., & Wagner, A. K. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00152-9 · Cited by 52
Update of thrombosis in multiple myeloma
Leebeek, F. W. G. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30103-7 · Cited by 53
Jakubowiak, A. J., Campioni, M., Benedict, Á., Houisse, I., Tichy, E., Giannopoulou, A., Aggarwal, S. K., Barber, B., & Panjabi, S. S. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1194278 · Cited by 51
Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States
Carlson, J. J., Guzauskas, G. F., Chapman, R. H., Synnott, P. G., Liu, S., Russo, E. T., Pearson, S. D., Brouwer, E., & Ollendorf, D. A. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.1.29 · Cited by 51
Current use of monoclonal antibodies in the treatment of multiple myeloma
Varga, C., Maglio, M. E., Ghobrial, I. M., & Richardson, P. G. G. (2018) · British Journal of Haematology · doi:10.1111/bjh.15121 · Cited by 51
Self-citationClinical impact of the CONUT score in patients with multiple myeloma
Okamoto, S., Ureshino, H., Kidoguchi, K., Kusaba, K., Kizuka-Sano, H., Sano, H., Nishioka, A., Yamaguchi, K., Kamachi, K., Itamura, H., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03844-2 · Cited by 51
O’Neal, J., Ritchey, J., Cooper, M. L., Niswonger, J., González, L. S., Street, E., Rettig, M. P., Gladney, S., Gehrs, L., Abboud, R., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01559-4 · Cited by 50
Jelı́nek, T., Žihala, D., Sevcikova, T., Sithara, A. A., Kapustová, V., Sahinbegovic, H., Venglár, O., Muroňová, L., Broskevičová, L., Nenarokov, S., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02206-w · Cited by 50
Monoclonal antibodies — A new era in the treatment of multiple myeloma
Jelı́nek, T., & Hájek, R. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.08.004 · Cited by 50
Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation
Çetin, A. E., Stevens, M. M., Calistri, N. L., Fulciniti, M., Olçum, S., Kimmerling, R. J., Munshi, N. C., & Manalis, S. R. (2017) · Nature Communications · doi:10.1038/s41467-017-01593-2 · Cited by 54
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma
Pazina, T., James, A. M., Colby, K. B., Yang, Y., Gale, A., Jhatakia, A., Kearney, A. Y., Graziano, R. F., Bezman, N., Robbins, M. D. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0579 · Cited by 50
Targeted Alpha-Particle Therapy for Hematologic Malignancies
Jurcic, J. G. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.09.002 · Cited by 50
Treatment of relapsed and refractory multiple myeloma
Lee, J. H., & Kim, S. (2020) · Blood Research · doi:10.5045/br.2020.s008 · Cited by 50
Emerging therapy options for IgG4-related disease
Lanzillotta, M., Fernández‐Codina, A., Culver, E. L., Ebbo, M., Martínez‐Valle, F., SCHLEINITZ, N., & Della‐Torre, E. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1902310 · Cited by 50
How I treat relapsed multiple myeloma
Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2022) · Blood · doi:10.1182/blood.2020008734 · Cited by 49
Self-citationNew Agents in Multiple Myeloma: An Examination of Safety Profiles
Bringhen, S., de Wit, E., & Dimopoulos, M. A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.05.003 · Cited by 49
Self-citationon behalf of the GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group, Arana, P., Paiva, B., Cedena, M. ‐., Puig, N., Cordón, L., Vídriales, M., Gutierrez, N. C., Chiodi, F., Burgos, L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.320 · Cited by 50
Self-citationTang, F., Malek, E., Math, S., Schmotzer, C. L., & Beck, R. C. (2018) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqy037 · Cited by 49
Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00103-x · Cited by 48
Self-citationSchmitz, S., Maguire, Á., Morris, J., Ruggeri, K., Haller, E., Kuhn, I. L., Leahy, J., Homer, N., Khan, A., Bowden, J., et al. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0509-7 · Cited by 49
Chakraborty, R., Riaz, I. B., Malik, S. U., Marneni, N., Garcia, A. M., Anwer, F., Khorana, A. A., Rajkumar, S. V., Kumar, S. K., Murad, M. H., et al. (2020) · Cancer · doi:10.1002/cncr.32682 · Cited by 48
Bruno, A. S., Willson, J., Opalińska, J., Nelson, J. J., Lunacsek, O. E., Stafkey-Mailey, D., & Willey, J. P. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1800451 · Cited by 48
Mateos, M., Granell, M., Oriol, A., Martínez‐López, J., Bladé, J., Hernández, M., Martín, J., Gironella, M., Lynch, M. J., Bleickardt, E. W., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14263 · Cited by 47
Self-citationAnti-Tumor Strategies by Harnessing the Phagocytosis of Macrophages
Li, S., Guo, Y.-L., Tian, J.-W., Zhang, H., Li, R., Gong, P., & Yu, Z. (2023) · Cancers · doi:10.3390/cancers15102717 · Cited by 47
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Moreau, P., van de Donk, N. W. C. J., Miguel, J. F. S., Lokhorst, H. M., Nahi, H., Ben‐Yehuda, D., Cavo, M., Cook, G., Delforge, M., Einsele, H., et al. (2016) · Drugs · doi:10.1007/s40265-016-0573-4 · Cited by 47
Self-citationNeri, P. E., Bahlis, N. J., & Lonial, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0184 · Cited by 49
Self-citationLeleu, X. P., Masszi, T., Bahlis, N. J., Viterbo, L., Baker, B., Gimsing, P., Maisnar, V., Samoilova, O. S., Rosiñol, L., Langer, C., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25134 · Cited by 47
Self-citationPaner, A., Patel, P. R., & Dhakal, B. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100643 · Cited by 47
Humbel, M., Bellanger, F., Fluder, N., Horisberger, A., Suffiotti, M., Fenwick, C. W., Ribi, C., & Comte, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645478 · Cited by 47
Siegel, D. S., Schiller, G. J., Song, K. W., Agajanian, R., Stockerl‐Goldstein, K., Kaya, H., Sebag, M., Samaras, C., Malek, E., Talamo, G., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16213 · Cited by 46
CAR T and CAR NK cells in multiple myeloma: Expanding the targets
Shah, U. A., & Mailankody, S. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101141 · Cited by 47
Kropivšek, K., Kachel, P., Götze, S., Wegmann, R., Festl, Y., Severin, Y., Hale, B. D., Mena, J., van Drogen, A., Dietliker, N., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00544-9 · Cited by 50
Raje, N. S., Moreau, P., Terpos, E., Benboubker, L., Grząśko, N., Holstein, S. A., Oriol, A., Huang, S., Beksaç, M., Kuliczkowski, K., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14483 · Cited by 47
Self-citationScreening and Diagnosis of Monoclonal Gammopathies: An International Survey of Laboratory Practice
Genzen, J. R., Murray, D. L., Ábel, G., Meng, Q. H., Baltaro, R. J., Rhoads, D. D., Delgado, J. C., Souers, R. J., Bashleben, C. P., Keren, D. F., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0128-cp · Cited by 46
Dimopoulos, M. A., Wang, M. L., Maisnar, V., Minařík, J., Bensinger, W., Mateos, M., Obreja, M., Blædel, J., & Moreau, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0583-7 · Cited by 46
Self-citationKuwahara‐Ota, S., Shimura, Y., Steinebach, C., Isa, R., Yamaguchi, J., Nishiyama, D., Fujibayashi, Y., Takimoto‐Shimomura, T., Mizuno, Y., Matsumura‐Kimoto, Y., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16881 · Cited by 46
Self-citationChakraborty, R., Cannella, L., Cottone, F., & Efficace, F. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30292-1 · Cited by 47
Immunotherapy in Multiple Myeloma
Soekojo, C. Y., Ooi, M. G. M., Mel, S. D., & Chng, W. J. (2020) · Cells · doi:10.3390/cells9030601 · Cited by 48
PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future
Jelı́nek, T., & Hájek, R. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1254856 · Cited by 46
Desantis, V., Savino, F. D., Scaringella, A., Potenza, M. A., Nacci, C., Frassanito, M. A., Vacca, A., & Montagnani, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092513 · Cited by 46
Costa, L. J., Lin, Y., Cornell, R. F., Martin, T. G., Chhabra, S., Usmani, S. Z., Jagannath, S., Callander, N. S., Berdeja, J. G., Kang, Y., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.10.013 · Cited by 45
Sonneveld, P., de Wit, E., & Moreau, P. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.007 · Cited by 45
Self-citationDaratumumab for the treatment of multiple myeloma
Touzeau, C., & Moreau, P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1322578 · Cited by 45
Self-citationRecent progress in relapsed multiple myeloma therapy: implications for treatment decisions
Moreau, P., & de Wit, E. (2017) · British Journal of Haematology · doi:10.1111/bjh.14780 · Cited by 46
Self-citationCell-based immunotherapy approaches for multiple myeloma
Kriegsmann, K., Kriegsmann, M., Cremer, M., Schmitt, M. W., Dreger, P., Goldschmidt, H., Müller‐Tidow, C., & Hundemer, M. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0346-9 · Cited by 46
Strategies to improve patient-reported outcome completion rates in longitudinal studies
Nielsen, L. K., King, M. T., Möller, S., Jarden, M., Andersen, C. L., Frederiksen, H., Gregersen, H., Klostergaard, A., Steffensen, M., Pedersen, P. T., et al. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02304-8 · Cited by 46
Bonello, F., Mina, R., Boccadoro, M., & Gay, F. (2019) · Cancers · doi:10.3390/cancers12010015 · Cited by 45
Is immunotherapy here to stay in multiple myeloma?
Rodríguez‐Otero, P., Paiva, B., Engelhardt, M. M., Prósper, F., & Miguel, J. F. S. (2017) · Haematologica · doi:10.3324/haematol.2016.152504 · Cited by 46
Emerging drugs and combinations to treat multiple myeloma
Larocca, A., Mina, R., Gay, F., Bringhen, S., & Boccadoro, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19269 · Cited by 44
Leblay, N., Maity, R., Hasan, F., & Neri, P. E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00636 · Cited by 49
Shah, N. D., Aiello, J., Avigan, D., Berdeja, J. G., Borrello, I., Chari, A., Cohen, A. D., Ganapathi, K. A., Gray, L., Green, D. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000734 · Cited by 47
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
Radocha, J., van de Donk, N. W. C. J., & Weisel, K. C. (2021) · Cancers · doi:10.3390/cancers13071571 · Cited by 45
Mansour, A., Wakkach, A., & Blin‐Wakkach, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00954 · Cited by 44
Laubach, J. P., Liu, C., Raje, N. S., Yee, A. J., Armand, P. A., Schlossman, R. L., Rosenblatt, J. M., Hedlund, J. A., Martin, M. G., Reynolds, C. H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1325 · Cited by 43
Self-citationPatel, K. K., Giri, S., Parker, T. L., Bar, N., Neparidze, N., & Huntington, S. F. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01849 · Cited by 43
Offidani, M., Corvatta, L., Morè, S., & Olivieri, A. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s267404 · Cited by 44
The promise and perils of immunotherapy
Lesch, S., & Gill, S. I. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004453c · Cited by 44
Zhang, T., Wang, S., Lin, T.-F., Xie, J., Zhao, L., Liang, Z., Li, Y., & Jiang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16987 · Cited by 42
High-risk Multiple Myeloma: Definition and Management
Joseph, N. S., Gentili, S., Kaufman, J. L., Lonial, S., & Nooka, A. K. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.018 · Cited by 42
Self-citationHari, P., Romanus, D., Palumbo, A. P., Luptakova, K., Rifkin, R. M., Tran, L. M., Raju, A., Farrelly, E., Noga, S. J., Blazer, M. A., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.12.012 · Cited by 42
Self-citationNooka, A. K., Gleason, C. L., Sargeant, M. O., Walker, M., Watson, M., Panjic, E. H., & Lonial, S. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00143 · Cited by 42
Self-citationKunacheewa, C., & Orlowski, R. Z. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-112017-091045 · Cited by 42
Self-citationWang, Y., Li, H. J., Xu, W. F., Pan, M., Qiao, C., Cai, J., Xu, J., Wang, M., & Zhang, J. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000320 · Cited by 42
Neurological complications of new chemotherapy agents
Zukas, A. M., & Schiff, D. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox115 · Cited by 43
Metadata
- Authors
- Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R. Z., Taniwaki, M., Röllig, C., Einsele, H., Wu, K. L., Singhal, A., San-Miguel, J., Matsumoto, M., Katz, J., Bleickardt, E., Poulart, V., Anderson, K. C., & Richardson, P.
- Affiliations
- Dalhousie University (CA)
- National and Kapodistrian University of Athens (GR)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Medical University of Silesia (PL)
- Centre Hospitalier Universitaire de Nantes (FR)
- Tel Aviv University (IL)
- University of Alberta (CA)
- Princess Margaret Cancer Centre (CA)
- Alfred Health (AU)
- Barts Health NHS Trust (GB)
- The University of Texas MD Anderson Cancer Center (US)
- Kyoto Prefectural University of Medicine (JP)
- Technische Universität Dresden (DE)
- Universitätsklinikum Würzburg (DE)
- Ziekenhuisnetwerk Antwerpen Stuivenberg (BE)
- AbbVie Biotherapeutics (United States) (US)
- National Hospital Organization (JP)
- Bristol-Myers Squibb (United States) (US)
- Dana-Farber Cancer Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-13
- Volume
- 373
- Issue
- 7
- Pages
- 621-631
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2201190784
- Semantic Scholar
- fb9d8d9019089b66fbe8ecd85963014c537e649e
- Cited by
- 1,322
- References
- 15
- Citations by year
- 2026: 29 · 2025: 60 · 2024: 63 · 2023: 87 · 2022: 95 · 2021: 147 · 2020: 174 · 2019: 132 · 2018: 154 · 2017: 187 · 2016: 160 · 2015: 33
- FWCI
- 139.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- AbbVie Biotherapeutics
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- elotuzumab, relapsed/refractory multiple myeloma, SLAMF7, lenalidomide, dexamethasone, progression-free survival, overall response rate, monoclonal antibodies, combination therapy, adverse events, lymphopenia, neutropenia, infusion reactions, interim analysis, overall survival
- MeSH terms
- Signaling Lymphocytic Activation Molecule Family, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Middle Aged, Multiple Myeloma, Receptors, Immunologic, Recurrence, Thalidomide, Disease-Free Survival, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
